Therapeutic Use of Myeloid Growth Factors for Chemotherapy-Induced Neutropenia in High Risk and Intermediate Risk Patients

This is a clinical practice guideline for patients who are receiving systemic therapy for solid tumors, lymphoma and non-myeloid malignancies, and that are deemed at increased risk for developing febrile neutropenia as a result of myelosuppression. The guideline reviews the therapeutic use of myeloid growth factors (granulocyte-colony stimulating factors (G-CSFs), filgrastim and pegfilgrastim) in the prevention of chemotherapy induced neutropenia (CIN) according to patient risk for developing CIN.